Joel P. Schneider, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 376, Room 104
- Frederick, MD 21702-1201
The Schneider group designs and characterizes novel materials for use in drug delivery, the delivery of cells, and antibacterial therapy.
Areas of Expertise
Our group develops novel materials for use in the delivery of therapeutics and as antibacterial agents. We are particularly interested in peptide and protein-based hydrogel materials formed by self-assembly mechanisms. Our work spans molecular conception, materials synthesis, nano- and bulk mechanical materials characterization, cell-material interactions, biocompatibility, and assessment of performance efficacy. Our basic research establishes how material composition and structure influences material function, and lays the foundation to ultimately translate materials to the clinic. We also develop and study membrane-perturbing peptides as drug delivery vehicles.
Surface-fill Hydrogel Attenuates the Oncogenic Signature of Complex Anatomical Surface Cancer in a Single Application
Antibacterial gel coatings inspired by the cryptic function of a mussel byssal peptide
Uncoupling the folding-function paradigm of lytic peptides to deliver impermeable inhibitors of intracellular protein-protein interactions
Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival
De novo design of selective membrane-active peptides via enzymatic control of their conformational bias on the cell surface
Joel P. Schneider, Ph.D.
Dr. Schneider received his Ph.D. in Organic Chemistry from Texas A&M University with Jeffery Kelly and then went on to the University of Pennsylvania School of Medicine, Department of Biochemistry and Biophysics where he was a George W. Raiziss Fellow with William DeGrado studying protein design. In 1999, he began his independent career at the University of Delaware as an assistant professor of Chemistry and Biochemistry and was promoted to associate and then full professor in 2009 with a secondary appointment in Materials Science and Engineering. He joined the NCI in 2010 as lab Chief of the newly established Chemical Biology Laboratory and was later appointed Deputy Director in 2015. He currently serves as the president of the American Peptide Society and Executive Editor of Biopolymers-Peptide Science.
|Position||Degree Required||Contact Name||Contact Email|
|Senior Investigator/Investigator - Chemical biology||Ph.D. or equivalent||Lori Hollidayemail@example.com|
Joel Schneider awarded the 2021 American Peptide Society Vincent du Vigneaud Award. Vincent du Vigneaud (May 18, 1901 – December 11, 1978) was an American biochemist who won the 1955 Nobel Prize in Chemistry “for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone,” a reference to his work on the cyclic peptide oxytocin. The Vincent du Vigneaud Awards recognize outstanding achievement in peptide research at mid-career. The du Vigneaud Awards are sponsored by Bachem, and are awarded to two deserving recipients at the biennial American Peptide Symposia. Link to https://www.americanpeptidesociety.org/duvigneaud-award/
Cancers that grow on the surfaces of organs and the linings of body cavities are notoriously difficult to treat. A new therapeutic hydrogel that can be injected or sprayed onto large surfaces could be an effective tool in fighting such cancers (Nat. Nanotechnol. 2021, DOI: 10.1038/s41565-021-00961-w).
2021 Mini-Retreat 'all vaxxed up, outside and sharing new results!'
2021 Mini-Retreat ' data hot off the press'
2019 CBL Retreat -Camp Greentop, Catoctin Mountain.
'Before masks were cool'
2019 Retreat Poster Session - 'Great Science'